1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tacrolimus (Tac) is mainly metabolized by cytochrome P450 3A isoenzymes. In a cohort of heart transplant recipients, we investigated the effect of CYP3A5, CYP3A4, and ABCB1/MDR1 polymorphisms on Tac dose requirements and the risk of developing new-onset diabetes after transplantation (NODAT).

          Related collections

          Author and article information

          Journal
          Transplant. Proc.
          Transplantation proceedings
          Elsevier BV
          1873-2623
          0041-1345
          Nov 2012
          : 44
          : 9
          Affiliations
          [1 ] Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain. beadimo@gmail.com
          Article
          S0041-1345(12)01044-5
          10.1016/j.transproceed.2012.09.062
          23146479
          41fde17a-987c-475f-87f3-bd5ae9dc5b72
          History

          Comments

          Comment on this article